NO985916L - Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler - Google Patents
Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikalerInfo
- Publication number
- NO985916L NO985916L NO985916A NO985916A NO985916L NO 985916 L NO985916 L NO 985916L NO 985916 A NO985916 A NO 985916A NO 985916 A NO985916 A NO 985916A NO 985916 L NO985916 L NO 985916L
- Authority
- NO
- Norway
- Prior art keywords
- chelating agents
- treatment
- metal chelates
- free radicals
- conditions caused
- Prior art date
Links
- 239000002738 chelating agent Substances 0.000 title abstract 2
- 229910052751 metal Inorganic materials 0.000 title abstract 2
- 239000002184 metal Substances 0.000 title abstract 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229910052748 manganese Inorganic materials 0.000 abstract 2
- 239000011572 manganese Substances 0.000 abstract 2
- 206010048610 Cardiotoxicity Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 231100000259 cardiotoxicity Toxicity 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Manufacture And Refinement Of Metals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Semiconductor Lasers (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Oppfinnelsen fremlegger bruk av en forbindelse av formel (I) eller et metallchelat eller salt av dette ved fremstilling av et behandlingsmiddel til bruk ved behandling eller forebygging av tilstander som skyldes forekomsten av frie radikaler i det menneskelige eller ikkemenneskelige legeme (hvor hver R' i formel (I) uavhengig av hverandre representerer hydrogen eller -CH2COR5, R5 representerer hydroksy, eventuelt hydroksylert alkoksy, amino eller alkylamido, hver R2 uavhengig av hverandre representerer en gruppe XYR6, hvor X representerer en binding eller en C,.3 alkylen- eller oksoalkylengruppe som eventuelt er substituert med en gruppe R7, Y representerer en binding, et oksygenatom eller en gruppe NR6, R6 er et hydrogenatom, en gruppe COOR8, en alkyl-, alkenyl-, sykloalkyl-, aryU eller aralkylgruppe som eventuelt er substituert med en eller flere av gruppene COOR8, CONRS2, NR82> OR8, =NR8, =0, OP(0)(OR8)R7 og OS03M, R7 er en hydroksy-, en eventuelt hydroksylert, eventuelt alkoksylert alkylgruppe, M er et hydrogenatom eller en ekvivalent av et fysiologisk aksepterbart kation, R3 representerer en C,.8 alkylengruppe, en 1,2- sykloalkylengruppe eller en l ,2-arylengruppe, og hver R4 uavhengig av hverandre representerer hydrogen eller C,.3-alkyl). Slike forbindelser er spesielt effektive til å lindre symptomer som er forbundet med reperfusjon av ischemisk vev og ved behandling eller forebygging av stråleskader.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9613182.6A GB9613182D0 (en) | 1996-06-24 | 1996-06-24 | Method |
PCT/GB1997/001722 WO1997049409A1 (en) | 1996-06-24 | 1997-06-24 | Chelating agents and their metal chelates for treating free radicals induced conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
NO985916D0 NO985916D0 (no) | 1998-12-17 |
NO985916L true NO985916L (no) | 1999-01-25 |
Family
ID=10795775
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO985917A NO985917L (no) | 1996-06-24 | 1998-12-17 | Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse |
NO985916A NO985916L (no) | 1996-06-24 | 1998-12-17 | Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO985917A NO985917L (no) | 1996-06-24 | 1998-12-17 | Reduksjon av kardiotoksisitet til antitumormiddel ved bruk av manganforbindelse |
Country Status (14)
Country | Link |
---|---|
US (2) | US6147094A (no) |
EP (2) | EP0936915B1 (no) |
JP (2) | JP4359651B2 (no) |
CN (2) | CN1228694A (no) |
AT (2) | ATE225178T1 (no) |
AU (2) | AU720570B2 (no) |
BR (1) | BR9709942A (no) |
CA (2) | CA2259150A1 (no) |
DE (2) | DE69717447T2 (no) |
GB (1) | GB9613182D0 (no) |
IL (1) | IL127733A0 (no) |
NO (2) | NO985917L (no) |
NZ (2) | NZ333357A (no) |
WO (2) | WO1997049390A1 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001527072A (ja) * | 1997-12-23 | 2001-12-25 | ニユコメド・イメージング・アクシエセルカペト | 一酸化窒素を放出するキレート化剤およびその治療上の使用 |
GB9727224D0 (en) * | 1997-12-23 | 1998-02-25 | Nycomed Imaging As | Method |
KR101312880B1 (ko) | 1999-10-01 | 2013-09-30 | 디엠아이 바이오사이언시스, 인크 | 금속 결합 화합물 및 그의 용도 |
FR2823977B1 (fr) * | 2001-04-26 | 2006-12-01 | Univ Rene Descartes | Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif |
GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
ES2388064T3 (es) | 2004-04-22 | 2012-10-08 | Celator Pharmaceuticals, Inc. | Formulaciones liposomales de agentes de antraciclina y análogos de citidina |
RU2433818C2 (ru) | 2005-08-31 | 2011-11-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества |
CA2708113C (en) | 2007-12-14 | 2017-08-22 | Pledpharma Ab | Compounds for use in the treatment of cancer |
BR112012000262A2 (pt) * | 2009-07-06 | 2016-02-16 | Pledpharma Ab | composição farmacêutica, e, método de tratamento de uma condição. |
PT2707030T (pt) | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
RU2765805C2 (ru) | 2012-01-05 | 2022-02-03 | Эгетис Терапьютикс Аб | Калмангафодипир, новое химическое соединение и другие смешанные комплексные соединения с металлами, способы получения, композиции и способы лечения |
AU2013327638B2 (en) | 2012-10-01 | 2018-06-14 | Mayo Foundation For Medical Education And Research | Cancer treatments |
US20150313921A1 (en) | 2012-11-02 | 2015-11-05 | Pledpharma Ab | Cancer Treatment Methods |
AU2015277494A1 (en) | 2014-06-16 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating myelomas |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
CA3014531A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
CA3035377A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Nanoparticle compositions for targeting t-cell cancers |
EP3506942B1 (en) | 2016-09-01 | 2022-11-16 | Mayo Foundation for Medical Education and Research | Carrier-pd-l1 binding agent compositions for treating cancers |
US11427637B2 (en) | 2016-09-06 | 2022-08-30 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
JP7025412B2 (ja) | 2016-09-06 | 2022-02-24 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | パクリタキセル-アルブミン-結合剤組成物並びに該組成物の使用及び製造方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES444380A1 (es) * | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
US5223243A (en) * | 1987-05-08 | 1993-06-29 | Salutar, Inc. | Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents |
US4842845A (en) * | 1987-05-08 | 1989-06-27 | Salutar, Inc. | Radioactive metal chelates for dipyridoxyl phosphate |
US4935518A (en) * | 1987-05-08 | 1990-06-19 | Salutar, Inc. | Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof |
US6204259B1 (en) * | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
-
1996
- 1996-06-24 GB GBGB9613182.6A patent/GB9613182D0/en active Pending
-
1997
- 1997-06-24 AT AT97928369T patent/ATE225178T1/de not_active IP Right Cessation
- 1997-06-24 JP JP50255798A patent/JP4359651B2/ja not_active Expired - Lifetime
- 1997-06-24 WO PCT/GB1997/001721 patent/WO1997049390A1/en active IP Right Grant
- 1997-06-24 CN CN97197429A patent/CN1228694A/zh active Pending
- 1997-06-24 CA CA002259150A patent/CA2259150A1/en not_active Abandoned
- 1997-06-24 AU AU32688/97A patent/AU720570B2/en not_active Ceased
- 1997-06-24 AU AU32689/97A patent/AU720621B2/en not_active Ceased
- 1997-06-24 DE DE69717447T patent/DE69717447T2/de not_active Expired - Lifetime
- 1997-06-24 NZ NZ333357A patent/NZ333357A/xx unknown
- 1997-06-24 BR BR9709942A patent/BR9709942A/pt not_active Application Discontinuation
- 1997-06-24 IL IL12773397A patent/IL127733A0/xx unknown
- 1997-06-24 JP JP50255898A patent/JP4162263B2/ja not_active Expired - Lifetime
- 1997-06-24 CA CA002258299A patent/CA2258299A1/en not_active Abandoned
- 1997-06-24 CN CN97197438A patent/CN1228703A/zh active Pending
- 1997-06-24 EP EP97928369A patent/EP0936915B1/en not_active Expired - Lifetime
- 1997-06-24 EP EP97928368A patent/EP0910360B1/en not_active Expired - Lifetime
- 1997-06-24 WO PCT/GB1997/001722 patent/WO1997049409A1/en active IP Right Grant
- 1997-06-24 NZ NZ333315A patent/NZ333315A/xx unknown
- 1997-06-24 DE DE69716104T patent/DE69716104T2/de not_active Expired - Lifetime
- 1997-06-24 AT AT97928368T patent/ATE228361T1/de not_active IP Right Cessation
-
1998
- 1998-12-17 US US09/213,246 patent/US6147094A/en not_active Expired - Lifetime
- 1998-12-17 US US09/213,290 patent/US6258828B1/en not_active Expired - Lifetime
- 1998-12-17 NO NO985917A patent/NO985917L/no not_active Application Discontinuation
- 1998-12-17 NO NO985916A patent/NO985916L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1997049390A1 (en) | 1997-12-31 |
CN1228703A (zh) | 1999-09-15 |
CN1228694A (zh) | 1999-09-15 |
AU720621B2 (en) | 2000-06-08 |
NO985917D0 (no) | 1998-12-17 |
NZ333315A (en) | 2000-07-28 |
GB9613182D0 (en) | 1996-08-28 |
CA2258299A1 (en) | 1997-12-31 |
ATE225178T1 (de) | 2002-10-15 |
AU3268897A (en) | 1998-01-14 |
NZ333357A (en) | 2000-08-25 |
DE69717447T2 (de) | 2003-09-11 |
JP4359651B2 (ja) | 2009-11-04 |
DE69716104D1 (de) | 2002-11-07 |
EP0936915A1 (en) | 1999-08-25 |
US6258828B1 (en) | 2001-07-10 |
BR9709942A (pt) | 1999-08-10 |
AU720570B2 (en) | 2000-06-08 |
EP0910360A1 (en) | 1999-04-28 |
NO985916D0 (no) | 1998-12-17 |
JP4162263B2 (ja) | 2008-10-08 |
JP2000513351A (ja) | 2000-10-10 |
ATE228361T1 (de) | 2002-12-15 |
CA2259150A1 (en) | 1997-12-31 |
IL127733A0 (en) | 1999-10-28 |
EP0936915B1 (en) | 2002-10-02 |
DE69717447D1 (de) | 2003-01-09 |
JP2000514044A (ja) | 2000-10-24 |
EP0910360B1 (en) | 2002-11-27 |
US6147094A (en) | 2000-11-14 |
AU3268997A (en) | 1998-01-14 |
DE69716104T2 (de) | 2003-05-28 |
WO1997049409A1 (en) | 1997-12-31 |
NO985917L (no) | 1999-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO985916D0 (no) | Chelaterende midler og metallchelater for bruk i behandling av tilstander forÕrsaket av frie radikaler | |
DE69826528D1 (de) | Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung | |
DK1039887T3 (da) | Anvendelse af aminothiolforbindelser til behandling af neuro- og nefrolidelser og terapeutiske toksiciteter | |
IL162214A (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
MY135985A (en) | Antitumor synergistic composition. | |
EA200100572A1 (ru) | Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии | |
EA200000282A1 (ru) | Способ введения таксана пациенту, нуждающемуся в лечении таксаном, способ лечения человека таксаном (варианты) | |
DK0912535T3 (da) | Konjugater af cis-docosahexaensyre og paclitaxel | |
AU2002236765A1 (en) | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent | |
MX9705235A (es) | Inhibidores de calpaina y/o catepsina b de oxazolidina substituida. | |
DE69703294D1 (de) | Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten | |
MXPA04004555A (es) | Dexrazoxano para tratamiento de cardiotoxicidad inducida por antitumor. | |
SG152907A1 (en) | Combinations for the treatment of inflammatory disorders | |
TW200518752A (en) | Combinations of drugs for the treatment of neoplasms | |
MY136610A (en) | Combined preparations comprising morpholine anthracyclines and platinum derivatives | |
NO20050640L (no) | Rutenium anticancer komplekser | |
YU24403A (sh) | Novi retinoidi za terapiju emfizema | |
WO2005011572A3 (en) | Combination of drugs for the treatment of neoplasms | |
GEP20032953B (en) | Antitumor Agents | |
MX9601994A (es) | Profarmacos de derivados de paclitaxel. | |
ATE485818T1 (de) | Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren | |
DK0613687T3 (da) | Anvendelse af pregnanderivat til behandling af tumorer | |
DE60111614D1 (de) | Taxan-derivate für die behandlung von krebs | |
DE69909636D1 (de) | Verwendung von methoxymorpholino doxorubicin zur behandlung eines lebertumor | |
NO943847L (no) | Fremgangsmåte for fremstilling av makrocykliske chelateringsmidler og dannelse av chelater og konjugater derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |